Gilead's deal with LEO Pharma includes a $250M upfront payment and up to $1.7B in milestones, impacting 2025 EPS by $0.15-$0.17. Our government trade tracker caught Pelosi’s 169% AI winner.

"2024 was a year of strong progress for LEO Pharma with double-digit growth in sales and another year of significantly ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps ... O’Day has overseen a period when Roche’s pharma division has been enjoying revenues of around $ ...

LEO Pharma delivered another year of strong progress ... The year has started strong with the January 2025 strategic partnership with Gilead to accelerate the STAT6 program. Follow-up on 2024 ...